Trial
NCT00996502
Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Columbia University
Collaborators
Genentech, Inc.
Condition
Prostate Cancer
Intervention
Docetaxel
Why stopped
Poor enrollment; PI left the institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-27